Integration of MRI and MRS approaches to monitor molecular imaging and metabolomic effects of trabectedin on a preclinical ovarian cancer model.
Animals
Cell Line, Tumor
Diffusion Magnetic Resonance Imaging
Female
Glucose
/ metabolism
Humans
Magnetic Resonance Imaging
Magnetic Resonance Spectroscopy
Metabolic Networks and Pathways
Metabolome
Metabolomics
Mice, SCID
Molecular Imaging
Ovarian Neoplasms
/ diagnostic imaging
Phospholipids
/ metabolism
Tissue Extracts
Trabectedin
/ therapeutic use
Xenograft Model Antitumor Assays
HER2 overexpression
MRI
MRS
metabolomics
ovarian cancer
phosphatidylcholine metabolism
Journal
NMR in biomedicine
ISSN: 1099-1492
Titre abrégé: NMR Biomed
Pays: England
ID NLM: 8915233
Informations de publication
Date de publication:
10 2019
10 2019
Historique:
received:
15
05
2018
revised:
14
06
2018
accepted:
13
08
2018
pubmed:
31
10
2018
medline:
2
4
2020
entrez:
31
10
2018
Statut:
ppublish
Résumé
Although several drugs are available to treat recurrences of human epithelial ovarian cancer (EOC), clinical responses often remain short lived and lead to only marginal improvements in patients' survival. One of the new drugs proposed for recurrent platinum-resistant EOC patients is trabectedin (Trab), a marine-derived antitumor agent initially isolated from the tunicate Ecteinascidia turbinata and currently produced synthetically. Predictive biomarkers of therapy response to this drug and the potential use of non-invasive functional MRI and MRS approaches for an early assessment of Trab efficacy have not yet been evaluated, although they might be relevant for improving the clinical management of EOC patients. In the present work we combined functional and spectroscopic magnetic resonance technologies, such as in vivo diffusion-weighted MRI and
Substances chimiques
Phospholipids
0
Tissue Extracts
0
Trabectedin
ID0YZQ2TCP
Glucose
IY9XDZ35W2
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e4016Informations de copyright
© 2018 John Wiley & Sons, Ltd.
Références
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7-30.
Luvero D, Milani A, Ledermann JA. Treatment options in recurrent ovarian cancer: latest evidence and clinical potential. Ther Adv Med Oncol. 2014;6(5):229-239.
Rigakos G, Razis E. BRCAness: finding the Achilles heel in ovarian cancer. Oncologist. 2012;17(7):956-962.
D'Incalci M. Trabectedin mechanism of action: what's new? Future Oncol. 2013;9(Suppl 12):5-10.
D'Incalci M, Galmarini CM. A review of trabectedin (ET-743): a unique mechanism of action. Mol Cancer Ther. 2010;9(8):2157-2163.
Monk BJ, Lorusso D, Italiano A, et al. Trabectedin as a chemotherapy option for patients with BRCA deficiency. Cancer Treat Rev. 2016;50:175-182.
D'Incalci M, Badri N, Galmarini CM, Allavena P. Trabectedin, a drug acting on both cancer cells and the tumour microenvironment. Br J Cancer. 2014;111(4):646-650.
Ventriglia J, Paciolla I, Cecere SC, et al. Trabectedin in ovarian cancer: is it now a standard of care? Clin Oncol. 2018;30(8):498-503.
Lorusso D, Scambia G, Pignata S, et al. Prospective phase II trial of trabectedin in BRCA-mutated and/or BRCAness phenotype recurrent ovarian cancer patients: the MITO 15 trial. Ann Oncol. 2016;27(3):487-493.
Nardo G, Favaro E, Curtarello M, et al. Glycolytic phenotype and AMP kinase modify the pathologic response of tumor xenografts to VEGF neutralization. Cancer Res. 2011;71(12):4214-4225.
Pisanu ME, Ricci A, Paris L, et al. Monitoring response to cytostatic cisplatin in a HER2(+) ovary cancer model by MRI and in vitro and in vivo MR spectroscopy. Br J Cancer. 2014;110(3):625-635.
Paris L, Podo F, Spadaro F, et al. Phosphatidylcholine-specific phospholipase C inhibition reduces HER2-overexpression, cell proliferation and in vivo tumor growth in a highly tumorigenic ovarian cancer model. Oncotarget. 2017;8(33):55022-55038.
Canese R, Mezzanzanica D, Bagnoli M, et al. In vivo magnetic resonance metabolic and morphofunctional fingerprints in experimental models of human ovarian cancer. Front Oncol. 2016;6:164.
Addley H, Moyle P, Freeman S. Diffusion-weighted imaging in gynaecological malignancy. Clin Radiol. 2017;72(11):981-990.
Iorio E, Ricci A, Bagnoli M, et al. Activation of phosphatidylcholine cycle enzymes in human epithelial ovarian cancer cells. Cancer Res. 2010;70(5):2126-2135.
Iorio E, Mezzanzanica D, Alberti P, et al. Alterations of choline phospholipid metabolism in ovarian tumor progression. Cancer Res. 2005;65(20):9369-9376.
Canese R, Pisanu ME, Mezzanzanica D, et al. Characterisation of in vivo ovarian cancer models by quantitative 1H magnetic resonance spectroscopy and diffusion-weighted imaging. NMR Biomed. 2012;25(4):632-642.
Granata A, Nicoletti R, Perego P, et al. Global metabolic profile identifies choline kinase alpha as a key regulator of glutathione-dependent antioxidant cell defense in ovarian carcinoma. Oncotarget. 2015;6(13):11216-11230.
Li SP, Padhani AR. Tumor response assessments with diffusion and perfusion MRI. J Magn Reson Imaging. 2012;35(4):745-763.
Orton MR, Messiou C, Collins D, et al. Diffusion-weighted MR imaging of metastatic abdominal and pelvic tumours is sensitive to early changes induced by a VEGF inhibitor using alternative diffusion attenuation models. Eur Radiol. 2016;26(5):1412-1419.
Kyriazi S, Collins DJ, Messiou C, et al. Metastatic ovarian and primary peritoneal cancer: assessing chemotherapy response with diffusion-weighted MR imaging-value of histogram analysis of apparent diffusion coefficients. Radiology. 2011;261(1):182-192.
Ferretti A, Knijn A, Raggi C, Sargiacomo M. High-resolution proton NMR measures mobile lipids associated with Triton-resistant membrane domains in haematopoietic K562 cells lacking or expressing caveolin-1. Eur Biophys J. 2003;32(2):83-95.
Iorio E, Ricci A, Pisanu ME, Bagnoli M, Podo F, Canevari S. Choline metabolic profiling by magnetic resonance spectroscopy. Methods Mol Biol. 2013;1049:255-270.
Romano M, Frapolli R, Zangarini M, et al. Comparison of in vitro and in vivo biological effects of trabectedin, lurbinectedin (PM01183) and Zalypsis(R) (PM00104). Int J Cancer. 2013;133(9):2024-2033.
Mabuchi S, Hisamatsu T, Kawase C, et al. The activity of trabectedin as a single agent or in combination with everolimus for clear cell carcinoma of the ovary. Clin Cancer Res. 2011;17(13):4462-4473.
Surov A, Meyer HJ, Wienke A. Correlation between apparent diffusion coefficient (ADC) and cellularity is different in several tumors: a meta-analysis. Oncotarget. 2017;8(35):59492-59499.
Surov A, Meyer HJ, Wienke A. Associations between apparent diffusion coefficient (ADC) and KI 67 in different tumors: a meta-analysis. Part 1: ADCmean. Oncotarget. 2017;8(43):75434-75444.
Lindgren A, Anttila M, Rautiainen S, et al. Primary and metastatic ovarian cancer: characterization by 3.0T diffusion-weighted MRI. Eur Radiol. 2017;27(9):4002-4012.
Li HM, Zhao SH, Qiang JW, et al. Diffusion kurtosis imaging for differentiating borderline from malignant epithelial ovarian tumors: a correlation with Ki-67 expression. J Magn Reson Imaging. 2017;46(5):1499-1506.
Vidic I, Egnell L, Jerome NP, et al. Support vector machine for breast cancer classification using diffusion-weighted MRI histogram features: preliminary study. J Magn Reson Imaging. 2017;47(5):1205-1216.
Peraldo Neia C, Cavalloni G, Chiorino G, Ostano P, Aglietta M, Leone F. Gene and microRNA modulation upon trabectedin treatment in a human intrahepatic cholangiocarcinoma paired patient derived xenograft and cell line. Oncotarget. 2016;7(52):86766-86780.
Glunde K, Bhujwalla ZM, Ronen SM. Choline metabolism in malignant transformation. Nat Rev Cancer. 2011;11(12):835-848.
Podo F, Canevari S, Canese R, Pisanu ME, Ricci A, Iorio E. MR evaluation of response to targeted treatment in cancer cells. NMR Biomed. 2011;24(6):648-672.
Pascucci B, Lemma T, Iorio E, et al. An altered redox balance mediates the hypersensitivity of Cockayne syndrome primary fibroblasts to oxidative stress. Aging Cell. 2012;11(3):520-529.
Tiziani S, Lodi A, Khanim FL, Viant MR, Bunce CM, Gunther UL. Metabolomic profiling of drug responses in acute myeloid leukaemia cell lines. PLoS ONE. 2009;4(1). e4251
Atmaca H, Bozkurt E, Uzunoglu S, Uslu R, Karaca B. A diverse induction of apoptosis by trabectedin in MCF-7 (HER2−/ER+) and MDA-MB-453 (HER2+/ER-) breast cancer cells. Toxicol Lett. 2013;221(2):128-136.
Canese R, Iorio E, Ricci A, Pisanu ME, Giannini M, Podo F. Metabolite quantification in tumours by magnetic resonance spectroscopy: objectives, results and perspectives. Curr Med Imaging Rev. 2009;5(2):110-127.